Symbiotec Pharmalab Ltd press release, Q2 FY27
Symbiotec recognised Rs. 53 crore of milestone revenue from its DCV licensing deal in Q2 FY27.
By ScoutQuest · · 1 min read
- Milestone revenue from DCV licensing deal, Q2 FY27
- Rs. 53 crore
- Adjusted EBITDA (excl. one-time IPO expense), Q2 FY27
- 94 (Rs. in Crs) (up 88% YoY)
- API operating revenue, Q2 FY27
- Rs. 227 crore (up 16% YoY)
- Release
- Results press release
- Period
- Q2 FY27
_Consolidated · Q2 & H1 FY27_
📊 Adjusted EBITDA (excl. one-time IPO expense), Q2 FY27: 94 (Rs. in Crs) (up 88% YoY)
📈 API operating revenue rose 16% YoY to Rs. 227 crore in Q2 FY27, with API EBITDA up 21% YoY to Rs. 71 crore and API gross margins above 60%, the company says.
🏭 EUGMP audits at the Rau and Pithampur plants in March 2026 brought approval certification for both plants, and USFDA audits in H1 FY27 brought EIR for both plants, the company says.
Also from Symbiotec Pharmalab
Symbiotec Pharmalab Q2 FY27: revenue up 43% to Rs. 280 crore, PAT up 169% to Rs. 52 crore
5 Nov 2026
Board approves Sept 2026 quarter and half-year results; limited review conclusion unmodified
5 Nov 2026
Symbiotec Pharmalab Q2 & H1FY27 earnings call on November 6, 2026, hosted by Avendus Spark
28 Oct 2026
More numbers
- Consolidated revenue, Q2 FY27280 (Rs. in Crs)
- Consolidated PAT, Q2 FY2752 (Rs. in Crs)
- Consolidated revenue, H1 FY27498 (Rs. in Crs)
- Consolidated PAT, H1 FY2766 (Rs. in Crs)
- Adjusted EBITDA (excl. one-time IPO expense), Q2 FY2794 (Rs. in Crs)
- API operating revenue, Q2 FY27227 (Rs. in Crs)
- API EBITDA, Q2 FY2771 (Rs. in Crs)
- DCV licensing revenue recognised, Q2 FY27Rs. 53 crs
- Net debt as on 30 September 2026~Rs. 314 crs
- Gross capex estimated by end FY27approx. Rs. 1,672 crs
- Gross capex invested, H1 FY27~Rs. 113 crs
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.